AB
ABT
Quarter ended Mar 31, 2024 · FY2024 Q1

Abbott Laboratories (ABT) Revenue — Quarter Ended Mar 31, 2024

Revenue for the quarter declined relative to the immediately preceding period, while it rose compared to the same period one year ago. The company's top line showed a sequential contraction but maintained year-over-year growth.

Key takeaway

Quarter ended Mar 31, 2024 · FY2024 Q1

Revenue for the quarter declined relative to the immediately preceding period, while it rose compared to the same period one year ago. The company's top line showed a sequential contraction but maintained year-over-year growth.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$10B

Revenue reported for this quarter.

Quarter-over-quarter

-2.7%

Change from the immediately preceding quarter.

Year-over-year

+2.2%

Change from the comparable year-ago quarter.

Trailing four quarters

$40.3B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Jun 30, 2023$10B-11.4%
Sep 30, 2023$10.1B-2.6%
Dec 31, 2023$10.2B+1.5%
Mar 31, 2024$10B+2.2%

Revenue performance

Compared with the prior quarter, revenue was lower. Versus the same quarter last year, revenue was higher.

Quarterly comparison

The current quarter's revenue matched the level seen about three quarters earlier, but was below the two intervening quarters.

What to watch

Cash and cash equivalents decreased from the end of the prior year, reflecting dividend payments and capital expenditures.